ADT, androgen deprivation therapy
Bone (2015) 81:45967.10.1016/j.bone.2015.08.006 31 IepsenEWLundgrenJRHartmannBPedersenOHansenTJorgensenNRet alGLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women
Uneven spacing is one of the more common causes of lumpy or asymmetric results, so marking the grid before starting, rather than freehanding it, reduces that risk considerably
Insulin and neurodegenerative disease: shared and specific mechanisms
Unfortunately, many people interested in using treatments like GLP-1, GLP-1/GIP, or Triple G don't qualify for insurance coverage, meaning they could end up paying more than $1,000 a month out of pocket
In 2021, the FDA approved Wegovy, a version of the drug with a higher GLP-1 concentration, for weight management purposes